The North America Protein A Resin Market is poised for significant growth driven by advancements in biopharmaceutical manufacturing, increased R&D investment, and robust demand for monoclonal antibodies. The market was valued at USD 390.5 Million in 2025 and is expected to reach USD 830.7 Million by 2035, expanding at a CAGR of 7.3% from 2024 to 2035. Leading companies such as Cytiva (GE Healthcare), Merck KGaA, and Repligen Corporation continue to innovate, enhancing the market's competitive landscape.
The economic impact of tariffs on "North America Protein A Resin Market".
Market Growth Drivers
Rising Demand for Monoclonal Antibodies: North America is a global leader in monoclonal antibody (mAb) development, and the surge in therapeutic mAbs has amplified the need for efficient protein purification. Protein A Resins play a crucial role in capturing and isolating antibodies, contributing to increased adoption. Companies like Thermo Fisher Scientific and Cytiva are investing heavily in advanced resins to support rapid and scalable bioprocessing, helping meet growing demand from both research and commercial production.
Expansion of Biopharmaceutical Manufacturing Facilities: The expansion of biomanufacturing infrastructure, especially in the US and Canada, is a major growth driver. Leading firms like Merck KGaA have invested in new production sites and automation technologies, bolstering the capacity for antibody-based therapeutics. This infrastructure growth creates heightened demand for high-performance Protein A resins, ensuring purity and efficiency in downstream processing.
Market Trends
Innovations in Next-Generation Protein A Resins: Recent market developments have focused on engineering resins with enhanced binding capacity, alkaline stability, and compatibility with single-use systems. For example, Repligen launched its NGL COVID-19 Capture Select affinity resin, facilitating high-purity antibody recovery and quick scale-up. The trend towards next-generation products is enabling biomanufacturers to achieve higher throughput and greater flexibility.
Shift Toward Continuous Bioprocessing: Many North American biopharmaceutical companies are shifting from traditional batch processing to continuous bioprocessing, which improves operational efficiency and product quality. Cytiva, for instance, has introduced Protein A resins optimized for continuous chromatography, supporting the growing market for flexible, cost-effective, and scalable production systems.
Market Opportunity
Personalized Medicine and Biosimilar Growth: Biopharma companies are investing in personalized medicines and biosimilars, opening new revenue streams for Protein A Resin manufacturers. Players such as Thermo Fisher Scientific are collaborating with emerging biotech firms to provide customized resin solutions, catering to a broader spectrum of therapeutic areas including oncology and autoimmune disorders.
Expansion into Cell and Gene Therapy: The ongoing expansion of cell and gene therapy manufacturing requires high-purity affinity resins, driving adoption in this niche yet fast-growing segment. Companies like Merck KGaA are actively innovating to develop novel Protein A resins tailored for these advanced therapies.
North America Protein A Resin Market Revenue (USD Million), 2020-2035
The revenue chart demonstrates a steady upward trajectory for the North America Protein A Resin market from 2020 through 2035. In 2020, the market stood at $250.4 million, driven by biopharma R&D growth. The trend continues as increasing adoption in therapeutics and expansion of production facilities boost demand. By 2025, market revenue reaches $390.5 million, climbing further with innovation and regulatory approvals. The chart peaks with projected revenue of $830.7 million in 2035, reflecting strong compound annual growth. This consistent rise underlines the market's resilience and opportunity for upstream and downstream players.
North America Protein A Resin Market by Region Share (%), 2025
The pie chart illustrates the market share distribution by major regions within North America in 2025. The United States leads by a significant margin, holding 72% of the market, underscoring its dominance in biopharmaceutical production and R&D capabilities. Canada follows with 19%, driven by government initiatives and growing biotech investments. Mexico accounts for 6%, reflecting emerging but promising growth in contract manufacturing. The rest of North America, including the Caribbean and smaller regions, comprise the remaining 3%. This distribution highlights the concentration of biomanufacturing power in the US, with potential for notable gains in Canada and Mexico.
Recent Developments
In February 2024, Cytiva announced the commercial launch of its MabSelect PrismA XT, a next-generation Protein A resin designed to deliver improved process economy and higher mAb capture capacity. This resin supports intensified processing for continuous manufacturing, helping customers scale up more efficiently and meet evolving regulatory standards.
Merck KGaA expanded its manufacturing capacity for chromatography resins, including Protein A, at its Danvers, Massachusetts site in April 2024. The $130 million investment aims to address surging demand from North American biomanufacturers and includes sustainability initiatives such as waste reduction and energy-efficient operations.
In March 2024, Repligen Corporation entered a strategic partnership with a leading Canadian CDMO to jointly develop advanced affinity resins tailored for bispecific and novel antibody formats. This alliance leverages Repligen’s expertise in resin engineering and the CDMO’s capabilities in antibody production, aiming to accelerate biopharma clients’ time to market.
Press Releases